Upcoming Cancer Brain & Nervous System

Developing new drug modalities to target ERK1/2 signalling

Funder BBSRC (part of UKRI)
Recipient organisation University of Cambridge
Funding Not disclosed
Period Sept 2028 — Sept 2028

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by BBSRC.

View the original record at the funder ↗

Related Research

Grants with similar aims, by meaning.

Developing new drug modalities to target ERK1 2 signalling
Developing a novel class of ERK5 inhibitors for the treatment of triple-negative breast cancer
Defining the role of ERK5 kinase and ERK5 transcriptional activities in cell migration and EMT using novel ERK5 inhibitors
Control of gene expression by the MAP kinase and SUMO pathways.
Regulation of ERK Signalling by the Scaffold Protein KSR1

Original classification

Studentship

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.